Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis

JAK2V617F causes >50% essential thrombocythemia (ET) and >90% polycythemia vera (PV). How such a single mutation causes distinct disorders remains a long-standing enigma. Here, we show that heterozygous JAK2V617F activates the transcription factor aryl hydrocarbon receptor (AhR), which biases MEP differentiation toward megakaryocytes in ET patients. In contrast, most PV patients' JAK2V617F exhibits a homozygous mutation that does not activate AhR. We found that JAK2V617F forms a heterodimer with JAK2 to recruit and activate STAT1, thereby inducing AhR activation and driving ET pathogenesis. However, JAK2 forms V617F homodimers in PV patients, which activate STAT5 and drive PV development. In addition to increasing platelet number, activated AhR may enhance platelet activity via the COX2-TXA2 axis. Importantly, targeting AhR inhibits thrombocytosis in JAK2V617F ET humanized mice. These findings not only elucidate the molecular mechanism of JAK2V617F ET but also provide a potential strategy for its treatment.

Authors

Institutions

Publication Details

Journal
The Journal of Experimental Medicine
Published
2025-10-15
DOI
https://doi.org/10.1084/jem.20250153
Citations
1
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis

Dongxiao Wu, Dianheng Wang, Nannan Zhou, Li Zhou et al.
1 citations
The Journal of Experimental Medicine
Myeloproliferative Neoplasms: Diagnosis and Treatment
1.63
article

Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis

Dongxiao Wu, Dianheng Wang, Nannan Zhou, Li Zhou, Yabo Zhou, Zhuo‐Yu An, Jiadi Lv, Shaoyang Lai, Jie Chen, Bo Huang, Zhenfeng Wang, Xiaohui Zhang, Peng Zhao
article en
1 citations

Abstract

JAK2V617F causes >50% essential thrombocythemia (ET) and >90% polycythemia vera (PV). How such a single mutation causes distinct disorders remains a long-standing enigma. Here, we show that heterozygous JAK2V617F activates the transcription factor aryl hydrocarbon receptor (AhR), which biases MEP differentiation toward megakaryocytes in ET patients. In contrast, most PV patients' JAK2V617F exhibits a homozygous mutation that does not activate AhR. We found that JAK2V617F forms a heterodimer with JAK2 to recruit and activate STAT1, thereby inducing AhR activation and driving ET pathogenesis. However, JAK2 forms V617F homodimers in PV patients, which activate STAT5 and drive PV development. In addition to increasing platelet number, activated AhR may enhance platelet activity via the COX2-TXA2 axis. Importantly, targeting AhR inhibits thrombocytosis in JAK2V617F ET humanized mice. These findings not only elucidate the molecular mechanism of JAK2V617F ET but also provide a potential strategy for its treatment.

The Journal of Experimental MedicineVol. 222(12)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Peking University People's Hospital (CN), Children’s Hospital of Fudan University Xiamen Branch (CN), Xiamen Maternal and Child Health Hospital (CN), Huazhong University of Science and Technology (CN)
Openalex Percentile: Top 13%
Myeloproliferative Neoplasms: Diagnosis and Treatment
1.63
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.